castle trial enrollment
60% Better Outcomes After Leaving Conventional Chronic Disease Management
60% Better Outcomes After Leaving Conventional Chronic Disease Management In the CASTLE phase 1/2 trial, participants experienced a 60% reduction in flare frequency compared with the 25% reduction seen with standard biologics, showing that switching from conventional management can dramatically improve disease control. The protocol is built around patient-centred